Insulin glargine
FDA approved · RxLong-acting basal insulin analog
Also known as: Lantus, Toujeo, Basaglar, Semglee, Soliqua 100/33, Lantus Solostar, Rezvoglar Kwikpen, Glargine, Toujeo Solostar, Lantus R
Strong, human-grade evidence
- Regulatory standing. FDA-approved prescription medicine
- Human trials. Backed by controlled human studies
- Registered human trials. 729 registered studies on ClinicalTrials.gov, most advanced Phase 4
- 2 cited sources. Includes primary / regulatory sources
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Insulin glargine is a modified form of human insulin designed to act slowly and steadily over about a day. After injection under the skin it forms small deposits that release insulin gradually, helping the body move glucose from the blood into cells and reducing glucose output from the liver.
What the evidence shows
Insulin glargine is FDA approved for improving blood sugar control in adults and children with type 1 diabetes and adults with type 2 diabetes, sold under names such as Lantus, Toujeo, Basaglar, and Semglee. Its effects are supported by a large body of human evidence, including hundreds of registered trials reaching Phase 4 and thousands of published papers.
Key facts
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
Pilot Study of Clinician-supported Patient Self-management of Hospital Insulin Therapy
BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
Glucose Control With Multiple Daily Insulin Injections In Diabetic Patients Hospitalized In A General Medicine Ward
Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks
Published literature
Live from Europe PMC. This is how much has been published, not how much is proven in humans.
Basal insulin and cardiovascular and other outcomes in dysglycemia.
The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.
Sources
- PubChem compound record (CID 118984454)
- FDA drug label on DailyMed
- Registered trials on ClinicalTrials.gov
- Published papers on Europe PMC
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.